Journal
ACS CENTRAL SCIENCE
Volume 6, Issue 11, Pages 2046-2052Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acscentsci.0c00855
Keywords
-
Categories
Funding
- ERC [638661]
- Royal Society (Industry Fellowship) [191037]
- BBSRC MIBTP program [BB/M01116X/1]
- Iceni Diagnostics Ltd
- EPSRC [EP/R511808/1]
- BBSRC [BB/S506783/1, BB/P01948X/1, BB/R002517/1, BB/S003339/1]
- MRC DTP [MR/N014294/1]
- Wellcome Trust [200870/Z/16/Z]
- Leverhulme Trust [RPG-2019087]
- Wellcome [208361/Z/17/Z]
- MRC [MR/S009213/1]
- Wellcome Trust [200870/Z/16/Z] Funding Source: Wellcome Trust
- BBSRC [BB/S003339/1, 1898615, BB/P01948X/2, BB/P01948X/1, BB/R002517/1] Funding Source: UKRI
- MRC [MR/S009213/1] Funding Source: UKRI
Ask authors/readers for more resources
There is an urgent need to understand the behavior of of the novel coronavirus (SARS-COV-2), which is the causative agent of COVID-19, and to develop point-of-care diagnostics. Here, a glyconanoparticle platform is used to discover that N-acetyl neuraminic acid has affinity toward the SARS-COV-2 spike glycoprotein, demonstrating its glycan-binding function. Optimization of the particle size and coating enabled detection of the spike glycoprotein in lateral flow and showed selectivity over the SARS-COV-1 spike protein. Using a virus-like particle and a pseudotyped lentivirus model, paper-based lateral flow detection was demonstrated in under 30 min, showing the potential of this system as a low-cost detection platform.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available